Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Interferon alfa-2b

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    69 result(s) found for: Interferon alfa-2b. Displaying page 1 of 4.
    1  2  3  4  Next»
    EudraCT Number: 2011-000759-18 Sponsor Protocol Number: 5172-003 Start Date*: 2011-07-13
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., USA
    Full Title: A Randomized, Active-Controlled Dose-Ranging Estimation Study to Evaluate the Safety, Tolerability, and Efficacy of Different Regimens of MK-5172 When Administered Concomitantly with Peginterferon ...
    Medical condition: Hepatitis C Virus Infection
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10019744 Hepatitis C PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-010273-20 Sponsor Protocol Number: 18081 Start Date*: 2012-11-28
    Sponsor Name:European organisation for research and treatment of Cancer
    Full Title: Adjuvant peginterferon alfa-2b for 2 years vs Observation in patients with an ulcerated primary cutaneous melanoma with T(2-4)bN0M0: a randomized phase III trial of the EORTC Melanoma Group.
    Medical condition: Ulcerated primary cutaneous melanoma >1mm (T2b-4bN0M0)
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004864 10027156 Skin melanomas (excl ocular) HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (Completed) DE (Completed) FR (Completed) AT (Completed) IT (Completed) DK (Completed) ES (Completed) NL (Completed) PT (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2012-005545-20 Sponsor Protocol Number: IJBNMDOCASTOR Start Date*: 2014-12-23
    Sponsor Name:Institut Jules Bordet
    Full Title: The CaStOR study Carcinoid Tumors after failure of Somatostatin analogs: a randomized phase III of Octreotide Lutate Peptid Receptor radionuclide Therapy (PRRT) versus inteRferon α-2b
    Medical condition: Progressive, unresectable, non-pancreatic gastrointestinal neuroendocrine tumors resistant to therapy with somatostatin analogues.
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052399 Neuroendocrine tumour PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-007446-54 Sponsor Protocol Number: HBV99-03 Start Date*: 2009-03-26
    Sponsor Name:Department of Gastroenterology and Hepatology, Erasmus MC, Rotterdam
    Full Title: LOWERING VIRAL LOAD WITH NUCLEOS(T)IDE ANALOGUES PRIOR TO PEG-INTERFERON ALFA-2B TREATMENT TO INCREASE SUSTAINED RESPONSE IN HBEAG-POSITIVE CHRONIC HEPATITIS B (PADD-STUDY)
    Medical condition: Chronic hepatitis B virus infection
    Disease: Version SOC Term Classification Code Term Level
    9.1 10008910 Chronic hepatitis B LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-002275-40 Sponsor Protocol Number: 2006-002275-40 Start Date*: 2007-01-24
    Sponsor Name:Uppsala University Hospital, Dept. of Medical Sciences
    Full Title: Prospective study of patients treated with pegylated interferon-alpha 2b (PegIntron) for metastasizing ileal/coecal carcinoids
    Medical condition: Metastasizing ileal/coecal carcinoids (WHO ICD-10 code: C17.9)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) DK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2009-016678-34 Sponsor Protocol Number: CRO1456 Start Date*: 2010-04-15
    Sponsor Name:Imperial College London
    Full Title: Exploring the Relationship Between Insulin Resistance and Interferon Resistance: Options to Overcome HCV Non-Response to Pegylated Interferon
    Medical condition: HCV infected patient who do not response to Pegylated Interferon. This study is trying to explore the relationship between insulin resistance and Interferon Resistance and the possible rule of Pio...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2010-024260-17 Sponsor Protocol Number: P08034 Start Date*: 2012-11-08
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase 3 Study to Assess the Efficacy and Safety of Boceprevir in Combination with Peginterferon alfa-2b Plus Ribavirin in Pediatric Subjects With Chronic Hepatitis C Genotype 1
    Medical condition: Chronic Hepatitis C
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10008912 Chronic hepatitis C PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) AT (Prematurely Ended) BE (Prematurely Ended) PT (Prematurely Ended) CZ (Prematurely Ended) ES (Prematurely Ended) IT (Prematurely Ended) PL (Prematurely Ended) NO (Prematurely Ended) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-005197-35 Sponsor Protocol Number: S1404 Start Date*: 2017-06-06
    Sponsor Name:Irish Clinical Oncology Research Group CLG, trading as Cancer Trials Ireland
    Full Title: A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma.
    Medical condition: High risk resected melanoma.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2007-001918-16 Sponsor Protocol Number: SoraPeg2007 Start Date*: 2007-12-20
    Sponsor Name:Universitätsklinikum Schleswig-Holstein, Campus Kiel
    Full Title: Combined Treatment of Sorafenib and pegylated interferon α2b in stage IV metastatic melanoma: a prospective non-randomized, multicenter Phase II Study SoraPeg Trial
    Medical condition: Die Studie ist eine nicht-randomisierte, multizentrische und prospektive Phase II-Studie. Im Rahmen der Studie soll eine kombinierte Behandlung mit Sorafenib und pegyliertem Interferon α2b im Stadi...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-003299-36 Sponsor Protocol Number: MK5172-012 Start Date*: 2011-11-09
    Sponsor Name:MERCK SHARP & DOHME CORP.
    Full Title: A Randomized, Partially Double-Blind, Active-Controlled, Dose-Ranging Estimation Study to Evaluate the Safety, Tolerability, and Efficacy of Different Regimens of MK-5172 When Administered Concom...
    Medical condition: HCV GT2/3
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10008912 Chronic hepatitis C LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-015121-37 Sponsor Protocol Number: ANRS HC 23 Start Date*: 2009-12-10
    Sponsor Name:ANRS
    Full Title: Etude multicentrique randomisée ouverte comparant la réduction virale et la tolérance de l’association IFN alpha-2b XL + ribavirine versus IFN peg alpha-2b + ribavirine chez des patients atteints d...
    Medical condition: Evaluation de l’activité antivirale d’injections hebdomadaires d’un nouvel interféron α-2b à libération prolongée formulé avec Medusa® (IFNα-2bXL) chez des patients atteints d’hépatite chronique v...
    Disease: Version SOC Term Classification Code Term Level
    12.0 10008912 Chronic hepatitis C LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2012-002772-13 Sponsor Protocol Number: MK3034-105-00 Start Date*: 2013-01-29
    Sponsor Name:MSD ITALIA S.R.L.
    Full Title: A multi-centre single-arm study to evaluate the efficacy and safety of BOCEPREVIR 44 weeks in addition to standard of care (SOC) in previously treatment failure (relapser, non-responders, both part...
    Medical condition: Chronic Hepatitis C
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004862 10008912 Chronic hepatitis C LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-002039-34 Sponsor Protocol Number: CABF656B2202 Start Date*: 2008-12-15
    Sponsor Name:Novartis Pharma Services AG
    Full Title: An open-label, randomized, multicenter, active-controlled, dose-ranging study to evaluate the safety and efficacy of albinterferon alfa-2b administered every 4 weeks plus ribavirin in interferon al...
    Medical condition: chronic hepatitis C
    Disease: Version SOC Term Classification Code Term Level
    9.1 10008912 Chronic hepatitis C LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) FR (Completed) PL (Completed) IT (Completed) GR (Prematurely Ended) GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-006208-52 Sponsor Protocol Number: IFN005 Start Date*: 2009-03-09
    Sponsor Name:Helix BioPharma Cooperation
    Full Title: Mono-centre, open-label study to investigate the multi-dose pharmacokinetics, efficacy and safety of Interferon alpha-2b Cream in women with a history of cytological diagnosed Pap IIID, with a con...
    Medical condition: cervical dysplasia (CIN I or CIN II; Pap IIID in the history, confirmed HPV+ status)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10008263 Cervical dysplasia LLT
    Population Age: Adults Gender: Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-000162-40 Sponsor Protocol Number: IFN 001 Start Date*: 2005-09-06
    Sponsor Name:Helix Product Development (Ireland) Limited
    Full Title: Treatment of genital warts with Interferon alpha-2b Cream: a randomized, double blind, placebo-controlled study
    Medical condition: Condylomata acuminata (genital warts)
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: SE (Completed) DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-001367-13 Sponsor Protocol Number: IASO_MF Start Date*: 2014-08-08
    Sponsor Name:Medizinische Universtät Wien, Universitätsklinik für Innere Medizin I
    Full Title: An open-label, prospective, single-centre, phase II study to assess dose and dose interval requirements with respect to efficacy and safety of AOP2014, PEG-Proline-Interferon alpha-2b, in patients ...
    Medical condition: Primary Myelofibrosis (grade MF-0 and MF-1) according to the WHO criteria
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10053134 Osteomyelofibrosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2008-000121-19 Sponsor Protocol Number: CapRI 2 Start Date*: 2008-08-11
    Sponsor Name:University of Heidelberg
    Full Title: A Randomized Multicentre Phase II Trial Comparing Adjuvant Therapy in Patients with Resected Pancreatic Adenocarcinoma Treated with Interferon Alpha-2b and 5-FU Alone or in Combination with Either ...
    Medical condition: Patients with Resected Pancreatic Adenocarcinoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10033608 Pancreatic cancer resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-003730-33 Sponsor Protocol Number: VEMUPLINT Start Date*: 2014-01-15
    Sponsor Name:Fondazione Melanoma ONLUS
    Full Title: Phase I-II study of the combination vemurafenib plus PEG-interferon in advanced melanoma patients harboring the V600BRAF mutation
    Medical condition: Evaluate the safety and the efficacy of Vemurafenib/PEG-interferon combination and the IFNAR1 upregulation lead by this treatment in advanced melanoma patients harboring the V600BRAF mutation
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10053571 Melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2014-003836-38 Sponsor Protocol Number: MK-5172-077 Start Date*: 2015-02-16
    Sponsor Name:Merck Corporation, Inc.
    Full Title: A Phase III, Open-Label Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172/MK-8742 versus Sofosbuvir/Pegylated Interferon/Ribavirin (PR) in Treatment-Naïve and PR...
    Medical condition: Hepatitis C
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004848 10019751 Hepatitis C virus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) LT (Completed) ES (Completed) NO (Completed) HU (Completed) DK (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2006-002703-13 Sponsor Protocol Number: HGS1008-C1060 Start Date*: 2007-03-20
    Sponsor Name:Human Genome Sciences, Inc.
    Full Title: A Phase 3, Randomized, Multi-Center Study to Evaluate the Efficacy and Safety of Albumin Interferon Alfa-2b (alb-IFN) in Combination with Ribavirin Compared with Peginterferon Alfa-2a (PEGASYS or P...
    Medical condition: Chronic hepatitis C (CHC) genotype 1.
    Disease: Version SOC Term Classification Code Term Level
    8.0 10008912 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) AT (Completed) FR (Completed) GB (Completed) ES (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 04 06:35:37 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA